Germany-based Boehringer Ingelheim has collaborated with the Yale Clinical and Translational Research Accelerator to introduce a study exploring digital health technologies for adults with heart failure, it was reported on Thursday.

The aim of the study is to determine the effect of three digital health technologies on patient results, clinical efficiencies and the improvement in patient quality of life.

Technology partners were chosen for assessment in the study based on their ability to increase engagement in disease management and offer information to healthcare providers. Those selected include Bodyport, a data-driven smart scale with enhanced cardiac monitoring directly accessible by providers; Noom, a data-driven, live coaching app featuring personalized plans for diet and weight management; and Conversa, an automated conversational platform designed to motivate patients to actively manage their health. The study design is to randomise patients to one of three technologies or usual care in a single study over six months.

Enrolment began in September with a goal of recruiting a total of 200 patients. Results will be published next year.